TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01212107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF Receptor
Description: LY2874455 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF Receptor
Description: LY2874455 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphate Binders
Study: NCT00174629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel/gemcitabine
Study: NCT01613885

Intervention type: OTHER
Intervention: No Intervention
Description: This study does not involve any intervention other than obtaining blood, nasal/cheek/throat/skin swabs, saliva, sputum, urine, and stool samples, breathing and skin tests.
Study: NCT01096251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT vs BST
Description: The comparison between the CBT and BST will be assessed in a two-arm randomized controlled trial. Participants will be randomly allocated in 2 groups (CBT and BST).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT vs BST
Description: The comparison between the CBT and BST will be assessed in a two-arm randomized controlled trial. Participants will be randomly allocated in 2 groups (CBT and BST).
Study: NCT04392076

Intervention type: PROCEDURE
Intervention: Image Guided Ablation
Description: Image Guided Ablation with RFA, MWA or CRYO of Renal Cancer

Intervention type: PROCEDURE
Intervention: Image Guided Ablation
Description: Image Guided Ablation with RFA, MWA or CRYO of Renal Cancer

Intervention type: PROCEDURE
Intervention: Image Guided Ablation
Description: Image Guided Ablation with RFA, MWA or CRYO of Renal Cancer
Study: NCT03423979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optilume™ BPH Prostatic DCB Dilation Catheter
Description: BPH Prostatic DCB treatment - The Optilume BPH Prostatic DCB Dilation Catheter System should be prepared per the Instructions for Use (IFU).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel will release to adjacent tissue after the balloon inflated in the urethra
Study: NCT01400412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Tenofovir disoproxil fumarate was administered orally as one 300 mg tablet once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: Emtricitabine was administered orally once a day as one 200 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: Emtricitabine was administered orally once a day as one 200 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Tenofovir disoproxil fumarate
Description: Placebo for tenofovir disoproxil fumarate was administered orally once a day as one tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Maraviroc
Description: Placebo for maraviroc was administered orally once a day as one tablet.
Study: NCT01117441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vindesine
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine
Description: see detailed protocol description
Study: NCT01400412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc was administered orally once a day as one 150 mg tablet.
Study: NCT01117441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunoxome
Description: see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
Study: NCT02586194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: Oral
Study: NCT03325049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The health-promoting conversations
Description: The health-promoting conversations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study: NCT04295772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: 100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
Study: NCT02586194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: Oral
Study: NCT01604187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
Study: NCT00492050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV on Day 8 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: 500 mg orally daily (or acyclovir 200 mg orally twice daily)
Study: NCT03603808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation
Description: Undergo electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV DNA Plasmids Therapeutic Vaccine VGX-3100
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01629498

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo image-guided IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo image-guided IMPT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo image-guided IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo image-guided IMPT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Beam Radiation Therapy
Description: Undergo image-guided IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo image-guided IMPT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01117441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunoxome
Description: see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine
Description: see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
Study: NCT03612531

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Receive manual therapy
Study: NCT01189851

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoperative Radiotherapy
Description: The Axxent eBx™ System utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed and provides brachytherapy when the physician chooses to deliver intracavitary or interstitial radiation to the surgical margins following lumpectomy for breast cancer.
Study: NCT03775109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canakinumab 150mg/ml solution for injection
Description: Canakinumab 150mg/ml solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100ml 5% Dextrose
Study: NCT03511664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles. After 4 cycles, patients were assessed for (1) evidence of response, (2) residual disease, and (3) tolerance to 177Lu-PSMA-617. If all 3 assessments were met the patient might received an additional 2 cycles of 177Lu-PSMA-617.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive/best standard of care
Description: Best supportive/best standard of care as defined by the local investigator

Intervention type: OTHER
Group type: OTHER
Intervention: Best supportive/best standard of care
Description: Best supportive/best standard of care as defined by the local investigator
Study: NCT04442139

Intervention type: OTHER
Intervention: Mini-Gastric Bypass
Description: Mini-Gastric Bypass bariatric surgery
Study: NCT00769522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: cycle 1: 375 mg/m² i.v., day 0, q28d~cycle 2-6: 500 mg/m² i.v., day 1, q28d

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: cycle 1: 375 mg/m² i.v., day 0, q28d~cycle 2-6: 500 mg/m² i.v., day 1, q28d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: cycle 1-6: 90mg/m² i.v., day 1-2, q28d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cycle 1-6: 250 mg/m² i.v., days 1-3, q28d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: cycle 1-6: 25 mg/m² i.v., days 1-3, q28d
Study: NCT02096237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IgE adsorber
Description: Two plasma volumes of each patient in the apheresis group will be treated per session
Study: NCT01117441

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: for eligibility for radiotherapy see detailed protocol description

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: for eligibility for radiotherapy see detailed protocol description

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: for eligibility for radiotherapy see detailed protocol description

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: for eligibility for radiotherapy see detailed protocol description

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: for eligibility for radiotherapy see detailed protocol description
Study: NCT01771042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary weight loss at 25% energy deficit
Description: Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary weight loss at 25% energy deficit
Description: Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary weight loss at 25% energy deficit
Description: Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary weight loss at 25% energy deficit
Description: Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.
Study: NCT00808561

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Alternative Fistula
Description: Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Forearm AV Graft
Description: a) ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
Study: NCT01117441

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: for eligibility for radiotherapy see detailed protocol description
Study: NCT00579098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 80 mg tablet taken by mouth daily for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken by mouth once daily for 90 days
Study: NCT02386631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Made Orthotic
Description: Provides longitudinal arch support
Study: NCT02969330

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulator

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: 300ml tap water with 75g glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 300ml tap water with 75g glucose
Study: NCT02436681

Intervention type: DEVICE
Group type: OTHER
Intervention: MIROMESH
Study: NCT02121522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807
Description: twice daily
Study: NCT00819299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcuFocus Corneal Inlay ACI 7000PDT
Description: corneal inlay
Study: NCT02001103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Pills of memantine, including 5 or 10 mg, all prepared in the same capsules as used in the placebo arm.~The Memantine 10 mg intervention arm will take 1 capsule of memantine and 1 capsule of placebo going into week 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Pills of memantine, including 5 or 10 mg, all prepared in the same capsules as used in the placebo arm.~The Memantine 10 mg intervention arm will take 1 capsule of memantine and 1 capsule of placebo going into week 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
Study: NCT02001103

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
Study: NCT03537573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Comparison
Description: Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids or acute pain who transition to chronic opioid therapy (\> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions, unsafe opioid prescribing, and transition to chronic opioid therapy (\> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
Study: NCT02526446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure
Description: The intervention consists of a total of 28 hours over a period of 8 weeks:~i) Individual learning and practice: The training session will be one-on-one provided twice a week for two consecutive weeks (5 hours) in the participant's home.~ii) Self-practice at home: From 3rd to 8th week, participant will engage in self-administered acupressure at home for 15 minutes twice a day for 6 weeks (21 hours).~iii) Home follow-up: During the 3rd and 4th week (i.e. after the 2-week training session), a 1-hour home visit will be conducted for reinforcement of learning and self-practice by the same team of trainers once a week for 2 weeks (2 hours).

Intervention type: OTHER
Group type: OTHER
Intervention: wait-list control
Description: The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
Study: NCT00446420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol, midazolam, fentanyl
Description: All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol, midazolam, fentanyl
Description: All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
Study: NCT03476278

Intervention type: OTHER
Intervention: Questionnaire
Description: Postoperative questionnaire, and records of complications in the peri-operative period
Study: NCT02279446

Intervention type: OTHER
Intervention: Intermediate Visual acuity (IVA) assessment
Description: Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5

Intervention type: OTHER
Intervention: Intermediate Visual acuity (IVA) assessment
Description: Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5

Intervention type: OTHER
Intervention: Intermediate Visual acuity (IVA) assessment
Description: Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5

Intervention type: OTHER
Intervention: Intermediate Visual acuity (IVA) assessment
Description: Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5
Study: NCT04020588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Will be administered for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Will be administered for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline 100mg
Description: Will be administered for 6 weeks
Study: NCT03750461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh Implantation
Description: Implantation of permanent mesh (BARD Soft Mesh) into the abdominal wall for reinforcement to prevent hernia formation
Study: NCT01511965

Intervention type: OTHER
Group type: OTHER
Intervention: autologous (cellular therapy)
Description: The skin sample, the preparation and implementation of the epidermal cells, are conducted on one day. A review of selected lesions is performed and a photograph. Second, are performed successively in a single day the collection of thin skin, preparing the cell suspension, a desepidermisation laser Erbium: YAG lesions of vitiligo to be grafted, and applicated.

Intervention type: OTHER
Group type: OTHER
Intervention: autologous (cellular therapy)
Description: The skin sample, the preparation and implementation of the epidermal cells, are conducted on one day. A review of selected lesions is performed and a photograph. Second, are performed successively in a single day the collection of thin skin, preparing the cell suspension, a desepidermisation laser Erbium: YAG lesions of vitiligo to be grafted, and applicated.
Study: NCT02406183

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: The SBRT dose will be escalated in 3 steps as described above and will be given on d39, d41 and d43

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3mg/kg will be given IV on d1, d22, d43 and d64
Study: NCT03841448

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Cemdisiran was administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cemdisiran
Description: Cemdisiran was administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Cemdisiran was administered by SC injection.